Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
68
ARQT Quote, Financials, Valuation and Earnings
Last price:
$26.97
Seasonality move
:
-8.25%
Day range:
$24.87 - $28.80
52-week range:
$11.86 - $31.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.91x
P/B ratio:
18.47x
Volume:
3.4M
Avg. volume:
1.3M
1-year change:
116.11%
Market cap:
$3.5B
Revenue:
$376.1M
EPS (TTM):
-$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$113M | $0.09 | 58.25% | -98.33% | $34.50 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$231M | $1.98 | 11.21% | 141.43% | $110.50 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 31.89% | 267.32% | $14.50 |
|
PCRX
Pacira Biosciences, Inc.
|
$201.9M | $0.90 | 10.43% | 608.41% | $29.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$28.57 | $34.50 | $3.5B | -- | $0.00 | 0% | 9.91x |
|
ADMA
ADMA Biologics, Inc.
|
$15.18 | $25.67 | $3.6B | 17.83x | $0.00 | 0% | 7.64x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$77.15 | $110.50 | $1.7B | 47.31x | $0.00 | 0% | 1.89x |
|
CRMD
CorMedix, Inc.
|
$7.35 | $14.86 | $579.1M | 3.58x | $0.00 | 0% | 2.47x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.33 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.01x |
|
PCRX
Pacira Biosciences, Inc.
|
$22.59 | $29.71 | $971.9M | 50.64x | $0.00 | 0% | 1.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
37.61% | -0.523 | 3.21% | 2.83x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.779 | 30.7% | 2.40x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -0.293 | 10.04% | 1.72x |
|
PCRX
Pacira Biosciences, Inc.
|
36.9% | -0.996 | 38.41% | 3.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$117.8M | $18.4M | -6% | -10.26% | 14.2% | $26.2M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
PCRX
Pacira Biosciences, Inc.
|
$130.9M | $13.2M | 1.58% | 2.81% | 7.33% | $57M |
Arcutis Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns ARQT or ADMA?
ADMA Biologics, Inc. has a net margin of 13.43% compared to Arcutis Biotherapeutics, Inc.'s net margin of 27.14%. Arcutis Biotherapeutics, Inc.'s return on equity of -10.26% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.90.98% $0.13 $303.7M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About ARQT or ADMA?
Arcutis Biotherapeutics, Inc. has a consensus price target of $34.50, signalling upside risk potential of 20.76%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 69.08%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is ARQT or ADMA More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.702, which suggesting that the stock is 70.199% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock ARQT or ADMA?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or ADMA?
Arcutis Biotherapeutics, Inc. quarterly revenues are $129.5M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Arcutis Biotherapeutics, Inc.'s net income of $17.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 9.91x versus 7.64x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.9.91x -- $129.5M $17.4M ADMAADMA Biologics, Inc.7.64x 17.83x $134.2M $36.4M
-
Which has Higher Returns ARQT or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 13.43% compared to Arcutis Biotherapeutics, Inc.'s net margin of 10.59%. Arcutis Biotherapeutics, Inc.'s return on equity of -10.26% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.90.98% $0.13 $303.7M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About ARQT or ANIP?
Arcutis Biotherapeutics, Inc. has a consensus price target of $34.50, signalling upside risk potential of 20.76%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.50 which suggests that it could grow by 43.23%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is ARQT or ANIP More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.702, which suggesting that the stock is 70.199% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.500, suggesting its less volatile than the S&P 500 by 50.037%.
-
Which is a Better Dividend Stock ARQT or ANIP?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ARQT or ANIP?
Arcutis Biotherapeutics, Inc. quarterly revenues are $129.5M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Arcutis Biotherapeutics, Inc.'s net income of $17.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 47.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 9.91x versus 1.89x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.9.91x -- $129.5M $17.4M ANIPANI Pharmaceuticals, Inc.1.89x 47.31x $227.8M $24.1M
-
Which has Higher Returns ARQT or CRMD?
CorMedix, Inc. has a net margin of 13.43% compared to Arcutis Biotherapeutics, Inc.'s net margin of 49.9%. Arcutis Biotherapeutics, Inc.'s return on equity of -10.26% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.90.98% $0.13 $303.7M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ARQT or CRMD?
Arcutis Biotherapeutics, Inc. has a consensus price target of $34.50, signalling upside risk potential of 20.76%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 102.14%. Given that CorMedix, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 CRMDCorMedix, Inc.4 0 0 -
Is ARQT or CRMD More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.702, which suggesting that the stock is 70.199% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock ARQT or CRMD?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or CRMD?
Arcutis Biotherapeutics, Inc. quarterly revenues are $129.5M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Arcutis Biotherapeutics, Inc.'s net income of $17.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 9.91x versus 2.47x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.9.91x -- $129.5M $17.4M CRMDCorMedix, Inc.2.47x 3.58x $104.3M $108.6M
-
Which has Higher Returns ARQT or FOLD?
Amicus Therapeutics, Inc. has a net margin of 13.43% compared to Arcutis Biotherapeutics, Inc.'s net margin of 0.91%. Arcutis Biotherapeutics, Inc.'s return on equity of -10.26% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.90.98% $0.13 $303.7M FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About ARQT or FOLD?
Arcutis Biotherapeutics, Inc. has a consensus price target of $34.50, signalling upside risk potential of 20.76%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.19%. Given that Arcutis Biotherapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Arcutis Biotherapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is ARQT or FOLD More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.702, which suggesting that the stock is 70.199% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock ARQT or FOLD?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or FOLD?
Arcutis Biotherapeutics, Inc. quarterly revenues are $129.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Arcutis Biotherapeutics, Inc.'s net income of $17.4M is higher than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 9.91x versus 7.01x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.9.91x -- $129.5M $17.4M FOLDAmicus Therapeutics, Inc.7.01x -- $185.2M $1.7M
-
Which has Higher Returns ARQT or PCRX?
Pacira Biosciences, Inc. has a net margin of 13.43% compared to Arcutis Biotherapeutics, Inc.'s net margin of 3.03%. Arcutis Biotherapeutics, Inc.'s return on equity of -10.26% beat Pacira Biosciences, Inc.'s return on equity of 2.81%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.90.98% $0.13 $303.7M PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B -
What do Analysts Say About ARQT or PCRX?
Arcutis Biotherapeutics, Inc. has a consensus price target of $34.50, signalling upside risk potential of 20.76%. On the other hand Pacira Biosciences, Inc. has an analysts' consensus of $29.71 which suggests that it could grow by 31.54%. Given that Pacira Biosciences, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 PCRXPacira Biosciences, Inc.3 2 0 -
Is ARQT or PCRX More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.702, which suggesting that the stock is 70.199% more volatile than S&P 500. In comparison Pacira Biosciences, Inc. has a beta of 0.244, suggesting its less volatile than the S&P 500 by 75.601%.
-
Which is a Better Dividend Stock ARQT or PCRX?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacira Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Pacira Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or PCRX?
Arcutis Biotherapeutics, Inc. quarterly revenues are $129.5M, which are smaller than Pacira Biosciences, Inc. quarterly revenues of $179.5M. Arcutis Biotherapeutics, Inc.'s net income of $17.4M is higher than Pacira Biosciences, Inc.'s net income of $5.4M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Pacira Biosciences, Inc.'s PE ratio is 50.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 9.91x versus 1.46x for Pacira Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.9.91x -- $129.5M $17.4M PCRXPacira Biosciences, Inc.1.46x 50.64x $179.5M $5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
